Tier 2 — strong
The Effect of Berberine on Lipid Profile, Liver Enzymes, and Fasting Blood Glucose in Patients with Non-alcoholic Fatty Liver Disease (NAFLD): A Randomized Controlled Trial
Medical journal of the Islamic Republic of Iran
2022
36:39
Bibliography
- PubMed
- PMID 36128280
- PubMed Central
- PMC9448505
- Funding
- Funding was not established from the accessible source; this is not a declaration of no funding.
- Competing interests
- The authors declared no competing interests in the publication.
Study snapshot
| Design | Randomized lifestyle-controlled study with nonstandardized boiled preparation |
|---|---|
| Model | Human participants; see population |
| Sample | 50 adults; 25 per arm |
| Intervention | Boiled preparation described as 6.25 g/day dried material; active alkaloid content not standardized |
| Duration | 45 days; described inconsistently as 6–7 weeks |
| Endpoints | Liver fat and liver enzymes; Body composition and weight; Metabolic biomarkers |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
- Berberine Food Sources: Barberry, Goldenseal and Plant ExtractsBerberine food sources explained: barberry fruit vs roots, goldenseal, Oregon grape, tree turmeric, tea and why plant lists do not establish doses.Read analysis
- Berberine and Fatty Liver: What MASLD Trials ShowBerberine and fatty liver evidence updated: compare older NAFLD studies with the 2026 BRAVO trial, liver-fat outcomes, fibrosis and formulation limits.Read analysis
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
